Rolofylline, an Adenosine A1−Receptor Antagonist, in Acute Heart Failure | Zendy

Barry M. Massie | Zendy; Christopher M. O’Connor | Zendy; Marco Metra | Zendy; Piotr Ponikowski | Zendy; John R. Teerlink | Zendy; Gad Cotter | Zendy; Beth Davison Weatherley | Zendy; John G.F. Cleland | Zendy; Michael M. Givertz | Zendy; Adriaan A. Voors | Zendy; Paul DeLucca | Zendy; George A. Mansoor | Zendy; Christina M. Salerno | Zendy; Daniel M. Bloomfield | Zendy; Howard C. Dittrich | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rolofylline, an Adenosine A₁−Receptor Antagonist, in Acute Heart Failure

Author(s) -

Barry M. Massie,

Christopher M. O’Connor,

Marco Metra,

Piotr Ponikowski,

John R. Teerlink,

Gad Cotter,

Beth Davison Weatherley,

John G.F. Cleland,

Michael M. Givertz,

Adriaan A. Voors,

Paul DeLucca,

George A. Mansoor,

Christina M. Salerno,

Daniel M. Bloomfield,

Howard C. Dittrich

Publication year - 2010

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0912613

Subject(s) - medicine , heart failure , placebo , odds ratio , clinical endpoint , renal function , cardiology , confidence interval , adverse effect , clinical trial , alternative medicine , pathology

Worsening renal function, which is associated with adverse outcomes, often develops in patients with acute heart failure. Experimental and clinical studies suggest that counterregulatory responses mediated by adenosine may be involved. We tested the hypothesis that the use of rolofylline, an adenosine A1-receptor antagonist, would improve dyspnea, reduce the risk of worsening renal function, and lead to a more favorable clinical course in patients with acute heart failure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research